Efficacy of blood copeptin level for the prediction of mortality of adult patients with sepsis: a meta-analysis

血液中血管加压素原水平预测成人脓毒症患者死亡率的有效性:一项荟萃分析

阅读:5

Abstract

BACKGROUND: Copeptin, the C-terminal fragment of provasopressin, has emerged as a potential prognostic biomarker in sepsis. However, its predictive accuracy for mortality in adult patients with sepsis remains uncertain. We conducted a systematic review and meta-analysis to evaluate the diagnostic performance of elevated blood copeptin levels for mortality prediction in this population. METHODS: We systematically searched PubMed, Embase, Web of Science, Wanfang Data, and CNKI from inception to 22 May 2025, for observational studies assessing copeptin levels at admission or within 48 h in adults with sepsis. Pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (AUC) were calculated using a random-effects model. Study quality was assessed using QUADAS-2. RESULTS: Ten prospective studies involving 1,637 patients were included. Pooled sensitivity and specificity of elevated copeptin for predicting mortality were 0.77 (95% CI: 0.70-0.83; I(2) = 52%) and 0.76 (95% CI: 0.67-0.83; I(2) = 86%), respectively. The pooled positive and negative likelihood ratios were 3.16 (95% CI: 2.33-4.29) and 0.30 (95% CI: 0.23-0.40), with a DOR of 10.40 (95% CI: 6.62-16.33). The summary AUC was 0.83 (95% CI: 0.79-0.86), indicating good overall prognostic accuracy. Subgroup analysis according to the cutoffs of copeptin did not significantly affect the results. No significant publication bias was detected (p = 0.58). CONCLUSION: Elevated blood copeptin levels within 48 h of sepsis diagnosis show good prognostic accuracy for short-term mortality in adult patients with sepsis. These findings support the potential clinical utility of copeptin as a risk stratification tool in sepsis management. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42024587540.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。